Lantern Pharma is trading up 5.2% at $0.69 as of 10:00 a.m. ET on October 21, 2026, with broader biotech strength a possible supporting factor; no company-specific announcement explaining the move was identified.
- The supplied market context reports XBI up 2.10%, alongside sector M&A and clinical-trial optimism.
- The investor-relations page lists October 8 and October 7 as its latest October releases. Recent patent coverage is not evidence of a new announcement today.